This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Bokhoven, A. Articles by Miller, G. J. Search for Related Content PubMed PubMed Citation Articles by van Bokhoven, A. Articles by Miller, G. J.

TSU-Pr1 and JCA-1 Cells Are Derivatives of T24 Bladder Carcinoma Cells and Are Not of Prostatic Origin¹

Department of Pathology [A. v. B., G. J. M.], Department of Medicine, Division of Medical Oncology [M. V-G.], and DNA Sequencing & Analysis Core [C. K.], University of Colorado Health Sciences Center, Denver, Colorado 80262

We have shown previously that the putative prostate carcinoma cell lines TSU-Pr1 and JCA-1 share a common origin. The observation that these cell lines have p53 and Ha-ras mutations identical to those in bladder carcinoma cell line T24 prompted us to investigate their possible interrelations. We used cytogenetics and DNA profiling to compare the genetic backgrounds of the three cell lines. At least 12 structural chromosomal abnormalities are shared between T24, TSU-Pr1, and JCA-1 cells. DNA profiles were identical for all three cell lines. These results clearly indicate that the cell lines TSU-Pr1 and JCA-1 are not of prostatic origin but are derivatives of the bladder carcinoma cell line T24. TSU-Pr1 and, to a lesser extent, JCA-1 are frequently used as models in prostate cancer research, and numerous publications have appeared based on these lines. Several other T24 cross-contaminants have been identified in the past, and some of these, such as ECV304, continue to be used under the wrong identity. Our findings highlight the insidious problem that can occur when information regarding cross-contamination does not reach individual researchers and/or the importance of the problem is not fully acknowledged.

This article has been cited by other articles:

				R. E. Schweppe, J. P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J. A. Knauf, J. A. Fagin, L. A. Marlow, J. A. Copland, R. C. Smallridge, et al. Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4331 - 4341. [Abstract] [Full Text] [PDF]

				F. Oberman, K. Rand, Y. Maizels, A. M. Rubinstein, and J. K. Yisraeli VICKZ proteins mediate cell migration via their RNA binding activity RNA, September 1, 2007; 13(9): 1558 - 1569. [Abstract] [Full Text] [PDF]

				A. G. Bharadwaj, K. Rector, and M. A. Simpson Inducible Hyaluronan Production Reveals Differential Effects on Prostate Tumor Cell Growth and Tumor Angiogenesis J. Biol. Chem., July 13, 2007; 282(28): 20561 - 20572. [Abstract] [Full Text] [PDF]

				Z Wu, K. McRoberts, and D Theodorescu The role of PTEN in prostate cancer cell tropism to the bone micro-environment Carcinogenesis, July 1, 2007; 28(7): 1393 - 1400. [Abstract] [Full Text] [PDF]

				S. A. Williams, R. F. Merchant, E. Garrett-Mayer, J. T. Isaacs, J. T. Buckley, and S. R. Denmeade A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease J Natl Cancer Inst, March 7, 2007; 99(5): 376 - 385. [Abstract] [Full Text] [PDF]

				S Humez, M Monet, G Legrand, G Lepage, P Delcourt, and N Prevarskaya Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 181 - 195. [Abstract] [Full Text] [PDF]

				K. Maiti, D. Y. Oh, J. S. Moon, S. Acharjee, J. H. Li, D. G. Bai, H.-S. Park, K. Lee, Y. C. Lee, N. C. Jung, et al. Differential Effects of Gonadotropin-Releasing Hormone (GnRH)-I and GnRH-II on Prostate Cancer Cell Signaling and Death J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4287 - 4298. [Abstract] [Full Text] [PDF]

				D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, and H. Hermeking Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer Cancer Res., May 15, 2005; 65(10): 4218 - 4227. [Abstract] [Full Text] [PDF]

				I. Y. Kim, D.-H. Lee, D. K. Lee, W. J. Kim, M. M. Kim, R. A. Morton, S. P. Lerner, and S. J. Kim Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1 Cancer Res., October 15, 2004; 64(20): 7355 - 7360. [Abstract] [Full Text] [PDF]

				F. Khwaja, J. Allen, J. Lynch, P. Andrews, and D. Djakiew Ibuprofen Inhibits Survival of Bladder Cancer Cells by Induced Expression of the p75NTR Tumor Suppressor Protein Cancer Res., September 1, 2004; 64(17): 6207 - 6213. [Abstract] [Full Text] [PDF]

				D. R. Chesire, T. A. Dunn, C. M. Ewing, J. Luo, and W. B. Isaacs Identification of Aryl Hydrocarbon Receptor as a Putative Wnt/{beta}-Catenin Pathway Target Gene in Prostate Cancer Cells Cancer Res., April 1, 2004; 64(7): 2523 - 2533. [Abstract] [Full Text] [PDF]

				C. Ren, L. Li, G. Yang, T. L. Timme, A. Goltsov, C. Ren, X. Ji, J. Addai, H. Luo, M. M. Ittmann, et al. RTVP-1, a Tumor Suppressor Inactivated by Methylation in Prostate Cancer Cancer Res., February 1, 2004; 64(3): 969 - 976. [Abstract] [Full Text] [PDF]

				J. R. Brody, S. S. Kadkol, M. C. Hauer, F. Rajaii, J. Lee, and G. R. Pasternack pp32 Reduction Induces Differentiation of TSU-Pr1 Cells Am. J. Pathol., January 1, 2004; 164(1): 273 - 283. [Abstract] [Full Text] [PDF]

				C. E. Petre-Draviam, S. L. Cook, C. J. Burd, T. W. Marshall, Y. B. Wetherill, and K. E. Knudsen Specificity of Cyclin D1 for Androgen Receptor Regulation Cancer Res., August 15, 2003; 63(16): 4903 - 4913. [Abstract] [Full Text] [PDF]

				E. Kikuchi, Y. Horiguchi, J. Nakashima, K. Kuroda, M. Oya, T. Ohigashi, N. Takahashi, Y. Shima, K. Umezawa, and M. Murai Suppression of Hormone-refractory Prostate Cancer by a Novel Nuclear Factor {kappa}B Inhibitor in Nude Mice Cancer Res., January 1, 2003; 63(1): 107 - 110. [Abstract] [Full Text] [PDF]

				H. T. Kim, B. C. Kim, I. Y. Kim, M. Mamura, D. H. Seong, J.-J. Jang, and S.-J. Kim Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells J. Biol. Chem., August 30, 2002; 277(36): 32510 - 32515. [Abstract] [Full Text] [PDF]

				I. Horikawa, P. L. Cable, S. J. Mazur, E. Appella, C. A. Afshari, and J. C. Barrett Downstream E-Box-mediated Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene Transcription: Evidence for an Endogenous Mechanism of Transcriptional Repression Mol. Biol. Cell, August 1, 2002; 13(8): 2585 - 2597. [Abstract] [Full Text] [PDF]